ArticleBMC cardiovascular disorders2026
Staged TAVR and TEER for complex multivalvular disease in advanced heart failure: a case report.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultivalvular heart disease complicated by advanced heart failure in elderly patients represents a major therapeutic challenge, particularly in the presence of complex anatomy, severe ventricular remodeling, and high surgical risk. Staged transcatheter strategies may offer a less invasive and individualized therapeutic alternative. An elderly patient with end-stage heart failure and severe ventricular remodeling was diagnosed with Sievers type I bicuspid aortic valve with mixed stenosis and severe regurgitation, complicated by functional moderate-to-severe mitral regurgitation. Given the patient's high surgical risk (STS-PROM 12%; EuroSCORE II 15%), a staged transcatheter strategy was adopted. Transfemoral TAVR was first performed with good prosthetic valve function and clinical improvement. Due to persistent symptomatic functional MR, subsequent transcatheter edge-to-edge repair (TEER) was performed three months later, resulting in significant MR reduction, symptomatic improvement, and favorable hemodynamic outcomes at follow-up. DISCUSSION: This case demonstrates the feasibility and clinical value of a staged transcatheter strategy in high-risk elderly patients with complex multivalvular disease and advanced heart failure. Sequential intervention allows reassessment of residual valve pathology, reduces procedural complexity, and lowers procedural risk compared with simultaneous multivalvular intervention. TAKE-HOME MESSAGE: A staged transcatheter strategy combining TAVR followed by TEER represents a safe, feasible, and effective therapeutic option for selected high-risk patients with complex multivalvular disease and advanced heart failure, offering individualized treatment and meaningful symptomatic improvement when surgical risk is prohibitive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.